AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer

Application based on results from the TROPION-Breast01 Phase III trial

Bio-Techne partners with Nikon Instruments for innovative spatial biology services

Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities

FDA Granted ODD to Utidelone Injectable from Biostar Pharma for treatment of breast cancer brain metastasis

Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide

The company had earlier announced about the approval received from the MHRA for Liraglutide

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations

NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer

If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy

lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary

Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market

WuXi Biologics breaks ground on CRDMO Center in Singapore

The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results